Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + bupivacaine is a combination of two amide-type local anesthetics used to provide regional anesthesia and postoperative pain relief. Lidocaine is characterized by a rapid onset of action, while bupivacaine provides a significantly longer duration of effect. Both agents work by binding to the intracellular portion of voltage-gated sodium channels, stabilizing the neuronal membrane and preventing the influx of sodium ions necessary for the initiation and conduction of nerve impulses. This specific 50:50 mixture was investigated by King Saud University in a Phase 3 clinical trial (NCT02282774) as a subtenon block adjunct to general anesthesia for patients undergoing vitreoretinal surgery, aiming to reduce postoperative pain, the oculocardiac reflex, and postoperative nausea and vomiting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + bupivacaine (King Saud University).